ribavirin has been researched along with mocetinostat in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Hegedüs, G; Hunyady, B; Miseta, A; Pár, A; Pár, G; Roth, E; Vincze, A | 1 |
| Hino, K; Hoshino, H; Hosoya, N; Kajiyama, Y; Kikuchi, K; Miyakawa, H; Takai, A | 1 |
1 trial(s) available for ribavirin and mocetinostat
| Article | Year |
|---|---|
[Effects of supplementation with the antioxidant flavonoid, silymarin, in chronic hepatitis C patients treated with peg-interferon + ribavirin. A placebo-controlled double blind study].
Topics: Adult; Aged; Alanine Transaminase; Antioxidants; Antiviral Agents; Double-Blind Method; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Malondialdehyde; Middle Aged; Oxidative Stress; Peroxidase; Polyethylene Glycols; Protective Agents; Ribavirin; RNA, Viral; Silymarin; Superoxide Dismutase; Treatment Outcome | 2009 |
2 other study(ies) available for ribavirin and mocetinostat
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
B-cell-activating factor affects the occurrence of thyroid autoimmunity in chronic hepatitis C patients treated with interferon alpha.
Topics: Age Factors; Antiviral Agents; Autoantibodies; Autoimmunity; B-Cell Activating Factor; Biomarkers; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Peroxidase; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; Sex Factors; Thyroid Gland | 2012 |